Quick Dispatch:
Your soul trial oral semaglutide cardiovascular outcomes results 2025 nejm Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your soul trial oral semaglutide cardiovascular outcomes results 2025 nejm Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes ships.
Need Help?
Questions about soul trial oral semaglutide cardiovascular outcomes results 2025 nejm Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for soul trial oral semaglutide cardiovascular outcomes results 2025 nejm Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes in your area.
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
22.08
New in the May 29, 2025, issue of NEJM: Sotatercept in Pulmonary Arterial Hypertension (ZENITH phase 3 trial) https://nej.md/4iYkLbj Oral Semaglutide and Cardiovascular Outcomes (SOUL trial) https://nej.md/4hHII5M Upadacitinib for Giant-Cell Arteritis
20.97
Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial
27.87
Oral Semaglutide in High-Risk Type 2 Diabetes: Cardiovascular Benefit Confirmed in the SOUL Trial
24.58
Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial
20.86
In patients with cardiovascular disease and overweight or obesity but no diabetes, semaglutide was superior to placebo in lowering the risk of major adverse cardiovascular events at a mean follow-up of 39.8
26.39
NEJM Editorial Fellow Harleen Marwah, MD, summarizes the SOUL trial. Read the full trial results at NEJM.org (link in bio). , , #ACC25 #Cardiology #ClinicalTrials #NEJM
24.26
